Enhancement of calcium uptake via the sarcoplasmic reticulum is a potent therapeutic strategy for dilated cardiomyopathy and heart failure

Bibliography

• DAVIES MJ: The cardiomyopathies: an overview. Heart (2000) 83 (4):469–474.
   Google Scholar
• GRAHAM RM, OWENS WA: Pathogenesis of inherited forms of dilated cardiomyopathy. N Engl. J Med. (1999) 341 (23):1759–1762.
   Google Scholar
• CHIEN KR: Stress pathways and heart failure. Cell (1999) 98 (5):555–558.
   Google Scholar
• ••A review focusing on stress pathways contributing to thedevelopment of DCM.
   Google Scholar
• ELLIOTT P: Car dio myo p athy. Diagnosis and manage-ment of dilated cardiomyopathy. Heart (2000) 84 (1):106–112.
   Google Scholar
• MOLKENTIN JD, LU JR, ANTOS CL et al.: A calcineurin-dep en den t transcriptional pathway for cardiac hypertrophy. Cell (1998) 93 (2):215–228.
   PubMedGoogle Scholar
• MINAMISAWA S, HOSHIJIMA M, CHU G et al.: Chronic phospholamban-sarcoplasmic reticulum calcium ATPase interaction is the critical calcium cycling defect in dilated cardiomyopathy. Cell (1999) 9 (3) :313–332.
   Google Scholar
• ••A genetic complementary study identifies that calciumcycling defect is critical in the development of DCM.
   Google Scholar
• BERS DM: Excitation-contraction coupling and cardiac contractile force. Dordrecht Kluwer Academic Publishers (1993).
   Google Scholar
• •An excellent textbook regarding EC coupling.
   Google Scholar
• MIYAMOTO MI, DEL MONTE F, SCHMIDT U et al.: Adenovir al gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure. Proc. Natl. Acad. Sci. USA (2000) 97 (2):793–798.
   PubMed Web of Science ®Google Scholar
• ••The first evidence to prove that complementation ofSERCA2a improves in vivo cardiac function in heart failure induced by pressure overload.
   Google Scholar
• MACLENNAN DH, RICE WJ, GREEN NM: The mechanism of Ca2+ transport by sarco(endo)plasmic reticulum Ca2+-ATPases. J Biol Chem. (1997) 272 (46):28815–28818.
   PubMed Web of Science ®Google Scholar
• •A thorough review of SERCA.
   Google Scholar
• SIMMERMAN HK, JONES LR: Phospholamban: protein structure, mechanism of action and role in cardiac function. Physiol Rev. (1998) 78(4):921–947.
   Google Scholar
• ••A most systematic and comprehensive review.
   Google Scholar
• TADA M, TOYOFUKU T: Molecular regulation of phospholamban function and expression. Trends Cardiovasc. Med. (1998) 8(8):330–340.
   Google Scholar
• LUO W, GRUPP IL, HARRER J et al: Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of beta-agonist stimulation. Circ. Res. (1994) 75:401–409.
   PubMed Web of Science ®Google Scholar
• MACDOUGALL LK, JONES LR, COHEN P: Identification of the major protein phosphatases in mammalian cardiac muscle which dephosphorylate phospho-lamban. Eur.J. Biochem. (1991) 196:725–734.
   PubMedGoogle Scholar
• HUANG B, WANG S, QIN D, BOUTJDIR M, EL-SHERIF N: Diminished basal phosphorylation level of phospho-lamban in the postinfarction remodeled rat ventricle: role of 13-adrenergic pathway, G, protein, phosphodi-esterase and phosphatases. Circ. Res. (1999) 85:848–855.
   PubMed Web of Science ®Google Scholar
• CHU G, LI L, SATO Y et al.: Pentameric assembly of phospholamban facilitates inhibition of cardiac function in viva J Biol. Chem. (1998) 2 7 3 (5033674–33680.
   Google Scholar
• KIMURA Y, ASAHI M, KURZYDLOWSKI K, TADA M, MACLENNAN DH: Phospholamban domain lb mutations influence functional interactions with the Ca2+-ATPase iso form of cardiac sarcoplasmic reticulum. J Biol. Chem. (1998) 273 (23):14238–14241.
   Google Scholar
• GWATHMEY JK, COPELAS L, MACKINNON R et al: Abnormal intracellular calcium handling in myocar-dium from patients with end-stage heart failure. Circ Res. (1987) 61(0:70–76.
   Google Scholar
• SCHVVINGER RH, BOHM M, SCHMIDT U et al.: Unchanged protein levels of SERCA II and phospholamban but reduced calcium uptake and Ca(24)-ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with non failing hearts. Circulation (1995) 92 (11):3220–3228.
   Google Scholar
• AKER DL, HASHIMOTO K, GRUPP IL et al.: Targeted overexpression of the sarcoplasmic reticulum Ca2+-ATPase increases cardiac contractility in transgenic mouse hearts. Circ Res. (1998) 83(12):1205–1214.
   Google Scholar
• HE H, GIORDANO FJ, HILAL-DANDAN R et al.: Overex-pression of the rat sarcoplasmic reticulum Ca2+ ATPase gene in the heart of transgenic mice acceler-ates calcium transients and cardiac relaxation. J Clin. Invest. (1997) 100 (2):380–389.
   Web of Science ®Google Scholar
• PERIASAMY M, REED TD, LIU LH et al: Impaired cardiac performance in heterozygous mice with a null mutation in the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 (SERCA2) gene. J Biol. Chem. (1999) 274:2556–2562.
   PubMed Web of Science ®Google Scholar
• LUO W, WOLSKA BM, GRUPP IL et al.: Phospholamban gene dosage effects in the mammalian heart. Circ. Res. (1996) 78:839–847.
   Google Scholar
• KOSS KL, GRUPP IL, KRANIAS EG: The relative phospho-lamban and SERCA2 ratio: a critical determinant of myocardial contractility. Basic Res. Cardiol. (1997) 92 (Supp1.1):17–24.
   Google Scholar
• LEHNART SE, SCHILLINGER W, PIESKE B, PRESTLE J, JUST H, HASENFUSS G: Sarcoplasmic reticulum proteins in heart failure. Ann. NY Acad. Sci. (1998) 853:220–230.
   PubMed Web of Science ®Google Scholar
• MOVSESIAN MA, KARIMI M, GREEN K, JONES LR: Ca (24)-tr an sp o r tin g ATPase,in nonfailing and failing human myocardium. Circulation (1994) 90 (2):653–657.
   Google Scholar
• NEUMANN J, ESCHENHAGEN T, JONES LR et al.: Increased expression of cardiac phosphatases in patients with end-stage heart failure. j Mol. Cell Cardiol. (1997) 29(0:265–272.
   PubMedGoogle Scholar
• DEL MONTE F, HARDING SE, SCHMIDT U et al.: Restora-tion of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2 a. Circulation (1999) 100 (23):2308–2311.
   PubMed Web of Science ®Google Scholar
• JOHNSON RG, JR.: Pharmacology of the cardiac sarcoplasmic reticulum calcium ATPase-phospholamban interaction. Ann. NY Acad. Sci. (1998) 853:380–392.
   PubMedGoogle Scholar
• ••A comprehensive review of SERCA2a activators and PLBinhibitors.
   Google Scholar
• SIMONIDES WS, BRENT GA, THELEN MH, VAN DER LINDEN CG, LARSEN PR, VAN HARDEVELD C: Characteri-zation of the promoter of the rat sarcoplasmic endoplasmic reticulum Ca2+-ATPase 1 gene and analysis of thyroid hormone responsiveness. j Biol. Chem. (1996) 271 (5032048–32056.
   Google Scholar
• MORISCOT AS, SAYEN MR, HARTONG R, WU P, DILLMANN WH: Transcription of the rat sarcoplasmic reticulum Ca2+ adenosine triphosphatase gene is increased by 3,5,3t-triiodothyronine receptor isoform-specific interactions with the myocyte-specific enhancer factor-2a. Endocrinology (1997) 138 (1):26–32.
   Google Scholar
• ARAI M, YOGUCHI A, TAKIZAWA T et al: Mechanism ofdoxorubicin-induced inhibition of sarcoplasmic reticulum Ca2+-ATPase gene transcription. Circ. Res. 2000 86:8–14.
   PubMed Web of Science ®Google Scholar
• HIZUMI Y, SASAKI S, SHIBUSAWA K, ISHIKAWA K, IKEMOTO F: Stimulation of sarcoplasmic reticulum Ca(24)-ATPase by gingerol analogues. Biol. Pharm. (1996) 19(10):1377–1379.
   Google Scholar
• ANTIPENKO AY, SPIELMAN Al, KIRCHBERGER MA: Interactions of 6-gingerol and ellagic acid with the cardiac sarcoplasmic reticulum Ca2+-ATPase. J. Pharmacol Exp. Ther. (1999) 290(1):227–234.
   Google Scholar
• BERREBI-BERTRAND I, LAHOURATATE P, LAHOURATATEV, CAMELIN JC, GUIBERT J, BRIL A: Mechanism of action of sarcoplasmic reticulum calcium-uptake activators- discrimination between sarco(endo)plasmic reticulum Ca2+ ATPase and phospholamban interac-tion. Eur.J. Biochem. (1997) 247 (3):801–809.
   Google Scholar
• PATIL AD, FREYER AJ, BEAN MF et al: The plakortones,novel bicyclic lactones from the sponge Plakortis halichondrioides: activators of cardiac SR-Ca2+ -pumping ATPase. Tetrahedran (1996) 52:377–394.
   Google Scholar
• ISHII T, SUNAMI O, SAITOH N, NISHIO H, TAKEUCHI T,HATA F: Inhibition of skeletal muscle sarcoplasmic reticulum Ca2+-ATPase by nitric oxide. FEBS Lett. (1998) 440 (1-2):218–222.
   Google Scholar
• SUTLIFF RL, HOYING JB, KADAMBI VJ, KRANIAS EG, PAULRJ: Phospholamban is present in endothelial cells and modulates endothelium-dependent relaxation. Evidence from phospholamban gene-ablated mice. Circ Res. (1999) 84(3):360–364.
   Google Scholar
• KIRIAZIS H, KRANIAS EG:models with alterations calcium-handling proteins. 62:321–351.
   Google Scholar
• •Informative review.
   Google Scholar
• HAGHIGHI K, KADAMBI VJ, KOSS KL etal.: In vitro and invivopromoter analyses of the mouse phospholamban gene. Gene (1997) 203 (2):199–207.
   Google Scholar
• MCTIERNAN CF, LEMSTER BH, FRYE CS, JOHNS DC, FELDMAN AM: Characterization of proximal transcrip-tion regulatory elements in the rat phospholamban promoter. j Mol Cell Cardiol. (1999) 31(12):2137–2153.
   Google Scholar
• HE H, MEYER M, MARTIN JL et al: Effects of mutant andantisense RNAofphospholamban on SRCa(2+)-ATPase activity and cardiac myocyte contractility. Circulation (1999) 100(9)974–980.
   Google Scholar
• EIZEMA K, FECHNER H, BEZSTAROSTI K et al.:Adenovirus-based phospholamban antisense expres-sion as a novel approach to improve cardiac contrac-tile dysfunction: comparison of a constitutive viral versus an endothelin-1 -responsive cardiac promoter. Circulation (2000) 101 (18) :2193–2199.
   PubMed Web of Science ®Google Scholar
• ROCKMAN HA, CHIEN KR, CHOI DJ et al: Expression of abeta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. Proc. Natl. Acad. ScL USA (1998) 95 (12):7000–7005.
   PubMed Web of Science ®Google Scholar
• BERREBI-BERTRAND I, SOUCHET M, CAMELIN JC, LAVILLE MP, CALMELS T, BRIL A: Biophysical interaction between phospholamban and protein phosphatase 1 regulatory subunit GM. FEBS Lett. (1998) 39 (3):224–230.
   Google Scholar
• MCKENNA E, SMITH JS, COLL KE et al.: Dissociation ofphospholamban regulation of cardiac sarcoplasmic reticulum Ca2+ATPase by quercetin.j Biol . Chem. (1996) 271 (4024517–24525.
   Google Scholar
• COLL KE, JOHNSON RG, JR., MCKENNA E: Relationship between phospholamban and nucleotide activation of cardiac sarcoplasmic reticulum Ca2+ adenosinetri-phosphatase. Biochemistry (1999) 38(8)2444–2451.
   Google Scholar
• CHIESI M, SCHVVALLER R: Reversal of phospholamban-induced inhibition of cardiac sarcoplasmic reticulum Ca(2+)-ATPase by tannin. Biochem. Biophys. Res. Commun. (1994) 202 (3):1668–1673.
   Google Scholar
• COLL KE, JOHNSON RG, JR., MCKENNA E: Nucleotide mimetics reverse phospholamban regulation in cardiac sarcoplasmic reticulum. Ann. NY Acad. ScL (1998) 853:267–269.
   Google Scholar
• TOYOSHIMA C, NAKASAKO M, NOMURA H, OGAWA H: Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution. Nature (2000) 405 (6787): 647–655.
   Google Scholar
• •High-resolution structural analysis of SERCAl.
   Google Scholar
• TOYOFUKU T, KURZYDLOWSKI K, TADA M, MACLENNAN DH: Identification of regions in the Ca(24)-ATPase of sarcoplasmic reticulum that affect functional association with phospholamban. j Biol. Chem. (1993) 268:2809–2815.
   PubMed Web of Science ®Google Scholar
• CHU G, LUO W, SLACK JP et al.: Compensatory mechanisms associated with the hyperdynamic function of phospholamban-deficient mouse hearts. Circ. Res. (1996) 79:1064–1076.
   PubMed Web of Science ®Google Scholar
• SANTANA LF, KRANIAS EG, LEDERER WJ: Calcium sparks and excitation-contraction coupling in phospholamban-deficient mouse ventricular myocytes. j Physiol (1997) 503 (Pt 1):21–29.
   Google Scholar
• DELLING U, SUSSMAN MA, MOLKENTIN JD: Re-evaluating sarcoplasmic reticulum function in heart failure. Nature Med. (2000) 9:942. Genetically engineeredin cardiac membraneAnn. Rev. Physiol. (2000)
   Google Scholar